Benign prostate hyperplasia.
Conditions
Interventions
Intervention 1: Intervention group: Magnesium hydroxide 8% is the main intervention and is administered at a dose of 30 cc per night, and tamsulosin capsules are given at a dose of 0.4 mg overnight. I
Sponsors
Shahroud University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
55 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients at the age of 55-75 years with benign prostatic hyperplasia referred to Imam Hossein Shahroud Hospital Patients who do not have an absolute indication of surgery Patients who have not received the drug for the treatment of benign prostatic hyperplasia
Exclusion criteria
Exclusion criteria: diabetic patients Patients with discopathy or other neurological diseases involving the bladder, prostate, anus and rectum All patients with a history of lower urinary tract surgery Patients with anorexia nervosa history Complications following drug and laxative consumption Smokers and opium users
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feeling bladder emptying. Timepoint: Before treatment and 13 weeks after treatment. Method of measurement: Prostate symptom scoring questionnaire.;Repetitive urination in less than 2 hours of bladder emptying. Timepoint: Before treatment and 13 weeks after treatment. Method of measurement: Prostate symptom scoring questionnaire.;Urinary flow rate. Timepoint: Before treatment and 13 weeks after treatment. Method of measurement: Prostate symptom scoring questionnaire.;Need for pressure to empty the bladder. Timepoint: Before treatment and 13 weeks after treatment. Method of measurement: Prostate symptom scoring questionnaire.;Urinary frequency during sleep. Timepoint: Before treatment and 13 weeks after treatment. Method of measurement: Prostate symptom scoring questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNaser Mogharabian
Shahroud University of Medical Sciences
Outcome results
None listed